K H Chan1, J S Tam, J S Peiris, W H Seto, M H Ng. 1. Department of Microbiology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China. dkhchan@netvigator.com
Abstract
BACKGROUND: Epstein-Barr virus (EBV) has been shown to be the cause of infectious mononucleosis (IM) and has more complicated associations with several malignant diseases. These EBV associated diseases provide a strong incentive for the development of an EBV vaccine. Most primary EBV infection during infancy and early childhood is mild or subclinical. Little is known about its infection in infancy. The pattern of EBV serological response during infancy may be important for vaccine management. OBJECTIVES: this study has served to clarify the epidemiology and serology of primary EBV infection during early infancy. STUDY DESIGN: longitudinal serum samples from 66 Hong Kong infants were tested for EBV antibodies by immunofluorescence. Cord blood and sequential serum samples from these infants were taken at birth and then at 4-month intervals up to 2 years of age. RESULTS: maternal antibodies were present at different levels in all cord blood specimens and in serum samples of 8 infants at 4-month of age. Evidenced by VCA-IgG seroconversion, 60.6% (40/66) infants were infected during the first 2 years of life. One episode occurred before 8 months of age but, thereafter and for the remaining 16 months of follow-up until the infants were 2 years of age, the infection occurred at essentially a constant rate affecting about 20% of the remaining seronegative infants every 4 months. CONCLUSIONS: the abrupt onset of the infection after a delay of 8 months is a remarkable feature of primary EBV infection during infancy, which implicates a protective role for maternal antibodies. Persisting maternal antibodies may additionally serve to contain the infection once it occurred. This may partly explain why, unlike during adolescence, primary EBV infection early in life is usually asymptomatic.
BACKGROUND: Epstein-Barr virus (EBV) has been shown to be the cause of infectious mononucleosis (IM) and has more complicated associations with several malignant diseases. These EBV associated diseases provide a strong incentive for the development of an EBV vaccine. Most primary EBV infection during infancy and early childhood is mild or subclinical. Little is known about its infection in infancy. The pattern of EBV serological response during infancy may be important for vaccine management. OBJECTIVES: this study has served to clarify the epidemiology and serology of primary EBV infection during early infancy. STUDY DESIGN: longitudinal serum samples from 66 Hong Kong infants were tested for EBV antibodies by immunofluorescence. Cord blood and sequential serum samples from these infants were taken at birth and then at 4-month intervals up to 2 years of age. RESULTS: maternal antibodies were present at different levels in all cord blood specimens and in serum samples of 8 infants at 4-month of age. Evidenced by VCA-IgG seroconversion, 60.6% (40/66) infants were infected during the first 2 years of life. One episode occurred before 8 months of age but, thereafter and for the remaining 16 months of follow-up until the infants were 2 years of age, the infection occurred at essentially a constant rate affecting about 20% of the remaining seronegative infants every 4 months. CONCLUSIONS: the abrupt onset of the infection after a delay of 8 months is a remarkable feature of primary EBV infection during infancy, which implicates a protective role for maternal antibodies. Persisting maternal antibodies may additionally serve to contain the infection once it occurred. This may partly explain why, unlike during adolescence, primary EBV infection early in life is usually asymptomatic.
Authors: Erwan Piriou; Amolo S Asito; Peter O Sumba; Nancy Fiore; Jaap M Middeldorp; Ann M Moormann; Robert Ploutz-Snyder; Rosemary Rochford Journal: J Infect Dis Date: 2012-02-01 Impact factor: 5.226
Authors: Kassandra L Munger; Kira Hongell; Marianna Cortese; Julia Åivo; Merja Soilu-Hänninen; Heljä-Marja Surcel; Alberto Ascherio Journal: Ann Neurol Date: 2019-07-03 Impact factor: 10.422
Authors: K H Chan; V C C Cheng; P C Y Woo; S K P Lau; L L M Poon; Y Guan; W H Seto; K Y Yuen; J S M Peiris Journal: Clin Diagn Lab Immunol Date: 2005-11
Authors: Sidney Ogolla; Ibrahim I Daud; Amolo S Asito; Odada P Sumba; Collins Ouma; John Vulule; Jaap M Middeldorp; Arlene E Dent; Saurabh Mehta; Rosemary Rochford Journal: Clin Vaccine Immunol Date: 2015-09-16
Authors: Arnold Reynaldi; Timothy E Schlub; Erwan Piriou; Sidney Ogolla; Odada P Sumba; Ann M Moormann; Rosemary Rochford; Miles P Davenport Journal: J Infect Dis Date: 2016-08-28 Impact factor: 5.226
Authors: Mario A Lorenzetti; Elena De Matteo; Hugo Gass; Paula Martinez Vazquez; Julia Lara; Pedro Gonzalez; María Victoria Preciado; Paola A Chabay Journal: PLoS One Date: 2010-10-22 Impact factor: 3.240